This presentation by Professor Krzysztof Narkiewicz focuses on “moving” management of arterial hypertension, analysing 2018 ESC guidelines. The word “move” refers on how a faster blood pression (BP) control can be obtained through triple combination therapy that, according to clinical data, is considered more effective.

Another important topic is perindopril/amlodipine/indapamide single pill combination (SPC) use in hypertension management and cardiovascular events prevention.

An ideal SPC treatment should be:

• Useful in various clinical conditions and different age groups.
• Available in double and triple combinations with several drugs.
• Supported by EBM and suitable in providing protection.

In this context, perindopril/amlodipine/indapamide use is supported by the recent international guidelines and clinical trials because:

• Suitable second step in hypertension management.
• Facilitates BP control in difficult to manage hypertension.
• Consistent with patient’s expectation.
• Provides optimal CV protection.